Glioblastomas are aggressive primary brain tumors with an inherent resistance to T cell-centric immunotherapy. We examined the dynamic changes of immune cells that occur in the tumor microenvironment of radio-immunotherapy-treated glioblastomas and identified a subpopulation of regulatory T cells with increased immunosuppressive activity. Depletion of this cell population improved survival in a mouse model of glioblastoma.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Aldape, K. et al. Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 16, 509–520 (2019). This review article presents seven key challenges that must be overcome to cure all patients with brain tumors, including poor ICB efficiency in glioblastoma.
Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 6, 1003–1010 (2020). This paper reports a clinical trial of α-PD-1 treatment in patients with recurrent glioblastoma.
Lim, S. A. et al. Lipid signalling enforces functional specialization of Treg cells in tumours. Nature 591, 306–311 (2021). This paper reports on the metabolic reprogramming of Treg cells with increased lipid signalling.
Wang, H. et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat. Immunol. 21, 298–308 (2020). This paper reports on the metabolic adaptation that regulates the survival and functions of intratumoral Treg cells, and the therapeutic potential of metabolic rewiring.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: van Hooren, L. et al. CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma. Nat. Cancer https://doi.org/10.1038/s43018-023-00547-6 (2023).
Rights and permissions
About this article
Cite this article
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors. Nat Cancer 4, 590–591 (2023). https://doi.org/10.1038/s43018-023-00551-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00551-w
